191 related articles for article (PubMed ID: 23556075)
1. The emerging role of lenalidomide in the management of lymphoid malignancies.
Hernandez-Ilizaliturri FJ; Batoo SA
Ther Adv Hematol; 2011 Feb; 2(1):45-53. PubMed ID: 23556075
[TBL] [Abstract][Full Text] [Related]
2. The emerging role of lenalidomide in the management of mantle cell lymphoma (MCL).
Dawar R; Hernandez-Ilizaliturri F
Best Pract Res Clin Haematol; 2012 Jun; 25(2):185-90. PubMed ID: 22687454
[TBL] [Abstract][Full Text] [Related]
3. Thalidomide and lenalidomide as new therapeutics for the treatment of chronic lymphocytic leukemia.
Awan FT; Johnson AJ; Lapalombella R; Hu W; Lucas M; Fischer B; Byrd JC
Leuk Lymphoma; 2010 Jan; 51(1):27-38. PubMed ID: 20055657
[TBL] [Abstract][Full Text] [Related]
4. Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study.
Palanca-Wessels MC; Czuczman M; Salles G; Assouline S; Sehn LH; Flinn I; Patel MR; Sangha R; Hagenbeek A; Advani R; Tilly H; Casasnovas O; Press OW; Yalamanchili S; Kahn R; Dere RC; Lu D; Jones S; Jones C; Chu YW; Morschhauser F
Lancet Oncol; 2015 Jun; 16(6):704-15. PubMed ID: 25925619
[TBL] [Abstract][Full Text] [Related]
5. Rituximab: a review of its use in chronic lymphocytic leukaemia, low-grade or follicular lymphoma and diffuse large B-cell lymphoma.
Keating GM
Drugs; 2010 Jul; 70(11):1445-76. PubMed ID: 20614951
[TBL] [Abstract][Full Text] [Related]
6. Bendamustine's emerging role in the management of lymphoid malignancies.
Rummel MJ; Gregory SA
Semin Hematol; 2011 Apr; 48 Suppl 1():S24-36. PubMed ID: 21530769
[TBL] [Abstract][Full Text] [Related]
7. A comprehensive review of lenalidomide therapy for B-cell non-Hodgkin lymphoma.
Witzig TE; Nowakowski GS; Habermann TM; Goy A; Hernandez-Ilizaliturri FJ; Chiappella A; Vitolo U; Fowler N; Czuczman MS
Ann Oncol; 2015 Aug; 26(8):1667-77. PubMed ID: 25712458
[TBL] [Abstract][Full Text] [Related]
8. A comprehensive review of lenalidomide in B-cell non-Hodgkin lymphoma.
Arora M; Gowda S; Tuscano J
Ther Adv Hematol; 2016 Aug; 7(4):209-21. PubMed ID: 27493711
[TBL] [Abstract][Full Text] [Related]
9. Immunomodulatory Drugs for the Treatment of B Cell Malignancies.
Ioannou N; Jain K; Ramsay AG
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445275
[TBL] [Abstract][Full Text] [Related]
10. Combined lenalidomide, low-dose dexamethasone, and rituximab achieves durable responses in rituximab-resistant indolent and mantle cell lymphomas.
Ahmadi T; Chong EA; Gordon A; Aqui NA; Nasta SD; Svoboda J; Mato AR; Schuster SJ
Cancer; 2014 Jan; 120(2):222-8. PubMed ID: 24122387
[TBL] [Abstract][Full Text] [Related]
11. Spotlight on rituximab in chronic lymphocytic leukemia, low-grade or follicular lymphoma, and diffuse large B-cell lymphoma.
Keating GM
BioDrugs; 2011 Feb; 25(1):55-61. PubMed ID: 21222497
[TBL] [Abstract][Full Text] [Related]
12. PI3Kδ activation, IL6 over-expression, and CD37 loss cause resistance to the targeting of CD37-positive lymphomas with the antibody-drug conjugate naratuximab emtansine.
Arribas AJ; Gaudio E; Napoli S; Yvon Herbaux CJ; Tarantelli C; Bordone RP; Cascione L; Munz N; Aresu L; Sgrignani J; Rinaldi A; Kwee I; Rossi D; Cavalli A; Zucca E; Stussi G; Stathis A; Sloss C; Davids MS; Bertoni F
bioRxiv; 2023 Nov; ():. PubMed ID: 38014209
[TBL] [Abstract][Full Text] [Related]
13. Lenalidomide in the treatment of chronic lymphocytic leukemia.
Itchaki G; Brown JR
Expert Opin Investig Drugs; 2017 May; 26(5):633-650. PubMed ID: 28388253
[TBL] [Abstract][Full Text] [Related]
14. Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials.
Smith SM; Pitcher BN; Jung SH; Bartlett NL; Wagner-Johnston N; Park SI; Richards KL; Cashen AF; Jaslowski A; Smith SE; Cheson BD; Hsi E; Leonard JP
Lancet Haematol; 2017 Apr; 4(4):e176-e182. PubMed ID: 28314699
[TBL] [Abstract][Full Text] [Related]
15. Lenalidomide in relapsed or refractory mantle cell lymphoma: overview and perspective.
Desai M; Newberry K; Ou Z; Wang M; Zhang L
Ther Adv Hematol; 2014 Jun; 5(3):91-101. PubMed ID: 24883181
[TBL] [Abstract][Full Text] [Related]
16. Update in the management of chronic lymphocytic leukemia.
Maddocks KJ; Lin TS
J Hematol Oncol; 2009 Jul; 2():29. PubMed ID: 19619273
[TBL] [Abstract][Full Text] [Related]
17. Obinutuzumab combined with lenalidomide for relapsed or refractory follicular B-cell lymphoma (GALEN): a multicentre, single-arm, phase 2 study.
Morschhauser F; Le Gouill S; Feugier P; Bailly S; Nicolas-Virelizier E; Bijou F; Salles GA; Tilly H; Fruchart C; Van Eygen K; Snauwaert S; Bonnet C; Haioun C; Thieblemont C; Bouabdallah R; Wu KL; Canioni D; Meignin V; Cartron G; Houot R
Lancet Haematol; 2019 Aug; 6(8):e429-e437. PubMed ID: 31296423
[TBL] [Abstract][Full Text] [Related]
18. Current and emerging treatments for chronic lymphocytic leukaemia.
Robak T; Jamroziak K; Robak P
Drugs; 2009; 69(17):2415-49. PubMed ID: 19911856
[TBL] [Abstract][Full Text] [Related]
19. Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Is It a Valid Treatment Option?
Mondello P; Steiner N; Willenbacher W; Ferrero S; Ghione P; Marabese A; Pitini V; Cuzzocrea S; Mian M
Oncologist; 2016 Sep; 21(9):1107-12. PubMed ID: 27382029
[TBL] [Abstract][Full Text] [Related]
20. Lenalidomide for the treatment of B-cell lymphoma.
Garciaz S; Coso D; Schiano de Colella JM; Bouabdallah R
Expert Opin Investig Drugs; 2016 Sep; 25(9):1103-16. PubMed ID: 27414850
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
